您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > PAR2(1-6)amide(human)(trifluoroacetate salt)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
PAR2(1-6)amide(human)(trifluoroacetate salt)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
PAR2(1-6)amide(human)(trifluoroacetate salt)图片
规格:98%
分子量:614.8
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议

产品介绍
A peptide agonist of PAR2
货号:ajcx25800
CAS:2379569-17-0
分子式:C28H54N8O7·XCF3COOH
分子量:614.8
溶解度:DMF: 30 mg/ml,DMSO: 15 mg/ml,Ethanol: 5 mg/ml,PBS (pH 7.2): 10 mg/ml
纯度:98%
存储:Store at -20°C
库存:现货

Background:

PAR2 (1-6) amide is a synthetic peptide agonist of proteinase-activated receptor 2 (PAR2) that corresponds to residues 1-6 of the amino terminal tethered ligand sequence of human PAR2 and residues 37-42 of the full-length sequence.1It binds to NCTC 2544 cells expressing human PAR2 (Ki= 9.64 µM in a radioligand binding assay) and induces calcium mobilization in the same cells (EC50= 0.075 µM).2PAR2 (1-6) amide (100 µM) reduces colony formation of A549 lung cancer cells.1It induces superoxide production and degranulation in isolated human eosinophils when used at a concentration of 500 µM.3PAR2 (1-6) amide (5 µmol/kg) induces tear secretion in rats when used in combination with amastatin .4


1.Bohm, S.K., Kong, W., Bromme, D., et al.Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2Biochem. J.314(Pt 3)1009-1016(1996) 2.Kanke, T., Ishiwata, H., Kabeya, M., et al.Binding of a highly potent protease-activated receptor-2 (PAR2) activating peptide, [3H]2-furoyl-LIGRL-NH2, to human PAR2Br. J. Pharmacol.145(2)255-263(2005) 3.Miike, S., McWilliam, A.S., and Kita, H.Trypsin induces activation and inflammatory mediator release from human eosinophils through protease-activated receptor-2J. Immunol.167(11)6615-6622(2001) 4.Nishikawa, H., Kawai, K., Tanaka, M., et al.Protease-activated receptor-2 (PAR-2)-related peptides induce tear secretion in rats: Involvement of PAR-2 and non-PAR-2 mechanismsJ. Pharmacol. Exp. Ther.312(2)324-331(2005)